Supplemental Figure 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Supplemental Figure 1. (A) Calu-1 cells were treated with VEGF (50 ng/ml) for 15 minutes and phospho-p38 levels were evaluated by Western blotting. VEGF treatment resulted in activation of p38, and this was blocked with the addition of VEGFR TKIs axitinib or sorafenib. (B) A549, H23, and Calu-1 cells express minimal levels of VEGFR1 as determined by ELISA assay. SKNAS neuroblastoma cells serve as a positive control.